T2 Biosystems' T2Candida Panel more sensitive than blood culture for monitoring patients on antifungal therapy

T2 Biosystems, Inc. (NASDAQ: TTOO) a company developing innovative diagnostic products to improve patient health, today announced that data on its T2Candida® Panel was presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, CA. The data demonstrate that T2Candida is more sensitive and rapid than blood culture for monitoring invasive candidiasis in proven cases of infection.

The T2Dx Instrument with T2Candida Panel seated in Stat Drawer

“This study was designed to take repeated blood samples from patients over time to determine the sensitivity of T2Candida compared to blood culture for monitoring patients on antifungal therapy,” said Peter Pappas, M.D., FACP, professor of medicine, division of infectious diseases, University of Alabama at Birmingham and principal investigator of the study. “The findings indicate that T2Candida may be a useful tool for monitoring patients and could facilitate initiation of cessation of therapy as well as improving source control.”

“Previous studies have demonstrated that blood culture may yield false negative test results when patients are on antifungal therapy,” said John McDonough, president and CEO of T2 Biosystems. “The results from this study demonstrate that T2Candida can provide more accurate results for patients who are on antifungals which can enable physicians to make better treatment decisions regarding the duration of therapy and controlling the source of the infection, including catheterization procedures and other medical interventions known to cause the disease.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues